Benemid (probenecid) Disease Interactions
There are 5 disease interactions with Benemid (probenecid):
Probenecid (Includes Benemid) ↔ Blood Dyscrasias
Severe Potential Hazard, Moderate plausibility
Applies to: Anemia, Bone Marrow Depression/Low Blood Counts
The manufacturer does not recommend the use of probenecid in patients with known blood dyscrasias. Aplastic anemia, leukopenia, hemolytic anemia and other anemia have been reported infrequently during administration of probenecid. Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency may increase the risk of probenecid-induced hemolytic anemia.
References
- Gutman AB "Uricosuric drugs with special reference to probenecid and sulfinpyrazone." Adv Pharmacol 4 (1966): 91-142
- "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.
- Sosler SD, Behzad O, Garratty G, et al "Immune hemolytic anemia associated with probenecid." Am J Clin Pathol 84 (1985): 391-4
Probenecid (Includes Benemid) ↔ Dehydration
Severe Potential Hazard, High plausibility
Applies to: Dehydration, Diarrhea, Vomiting
Probenecid may promote lithiasis by increasing uric acid concentration in the renal tubules. Adequate hydration is necessary during therapy. Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk for the development of uric acid kidney stones and should be encouraged to consume additional amounts of liquid or given intravenous fluid. In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended. Maintenance of a slightly alkaline or neutral urine is also desirable.
References
- "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.
- Gutman AB "Uricosuric drugs with special reference to probenecid and sulfinpyrazone." Adv Pharmacol 4 (1966): 91-142
Probenecid (Includes Benemid) ↔ Uric Acid Nephrolithiasis
Severe Potential Hazard, High plausibility
Applies to: Uric Acid Nephrolithiasis, History - Nephrolithiasis, Gouty Nephropathy
The use of probenecid is not recommended in patients with a history of uric acid nephrolithiasis or a urinary urate excretion greater than 750 mg/24 hr. Probenecid may promote lithiasis by increasing uric acid concentration in the renal tubules. Adequate hydration is necessary during treatment. In general, a fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended. Maintenance of a slightly alkaline urine is also desirable.
References
- "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.
- Gutman AB "Uricosuric drugs with special reference to probenecid and sulfinpyrazone." Adv Pharmacol 4 (1966): 91-142
Probenecid (Includes Benemid) ↔ Pud
Moderate Potential Hazard, Low plausibility
Applies to: Peptic Ulcer, History - Peptic Ulcer
The manufacturer states that probenecid should be used with caution in patients with a history of peptic ulcer. Uricosuric agents can cause upper gastrointestinal irritation and aggravate or reactivate peptic ulcer. However, these effects have primarily been reported with another uricosuric agent, sulfinpyrazone. GI effects associated with probenecid are usually limited to nausea, vomiting, and anorexia.
References
- "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.
Probenecid (Includes Benemid) ↔ Renal Dysfunction
Moderate Potential Hazard, High plausibility
Applies to: Renal Dysfunction
Probenecid may not be effective in patients with chronic renal insufficiency, particularly when glomerular filtration rate is 30 mL/min or less. Probenecid has been used in patients with some renal impairment but dosage requirements may be increased.
References
- Scott JT, O'Brien PK "Probenecid, nephrotic syndrome, and renal failure." Ann Rheum Dis 27 (1968): 249-52
- "Product Information. Benemid (probenecid)." Merck & Co, Inc, West Point, PA.
Benemid (probenecid) drug Interactions
There are 349 drug interactions with Benemid (probenecid)
See also...
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No information available. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
